Authors
Latest:
Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLLJan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.
Latest:
BTK Degraders and Other Targets in Mantle Cell LymphomaExperts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.
Latest:
Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPCEleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Latest:
PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian CancerPARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.
Latest:
Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R MyelomaBertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.
Latest:
Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid TumorsMiguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.
Latest:
Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALLAnne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.
Latest:
Dr. Olopade on Racial Disparities in Breast Cancer OutcomesOlufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.
Latest:
Dr Allan on Efforts to Clarify the Optimal Treatment Sequence in CLLJohn N. Allan, MD, discusses ongoing efforts to address areas of uncertainty regarding the optimal sequencing strategy in CLL.
Latest:
Dr Kambhampati on the Rationale For Evaluating Real-World Outcomes With Brexu-Cel in MCLSwetha Kambhampati, MD, discusses the rationale for evaluating outcomes with in a subgroup anlaysis of patients with relapsed/refractory mantle cell lymphoma, and how prior data from the phase 3 ZUMA-2 study supported the inception of this trial.
Latest:
Whole Genome Sequencing for AML/MDS Risk StratificationTwo clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.
Latest:
Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDSSomedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.
Latest:
Exciting NSCLC Data Updates from ESMO 2022The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
Latest:
Location Matters: US Patients With Adult T-Cell Leukemia/Lymphoma Have Distinct Clinical, Genetic FeaturesAdult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.
Latest:
Roswell Park Experts to Showcase Groundbreaking Hematology Research at 66th ASH Annual MeetingMore than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.
Latest:
Dr Dotan on Treating Geriatric Patients With Gastroesophageal CancerEfrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.
Latest:
Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Latest:
Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian CancerDavid M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.
Latest:
Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid TumorsAnna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.
Latest:
Dr Tarantino on Advances Allowing for Tailored Treatment in HER2+ Breast CancerPaolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.
Latest:
A Prayer for a More Equitable FutureRussell J. Ledet, PhD, discusses being a Black man in the field of oncology.
Latest:
The Mullin SistersA breast surgical oncology fellow tells the story of how 3 women in his family helped shape his career and provide a purpose for his passion.
Latest:
Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLCJaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.
Latest:
Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C MutationJayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.
Latest:
Taking Back Our Empathy: Reflections on a New Model of Medical EducationBharat Sanders sheds light on how patient-centered medical education put him behind the eyes of the patient and fundamentally changed the way he practices medicine.
Latest:
Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in MyelomaMonalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.
Latest:
Exciting Treatment Opportunities in mCRCClosing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Latest:
Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in PracticeThis episode explores management strategies for hematologic toxicities arising within the first 3 weeks of treatment with HER3-DXd, discusses the potential integration of HER3-DXd into clinical practice upon approval, and identifies unmet needs and suitable patient populations for future clinical trials evaluating HER3-DXd based on insights from the HERTHENA-Lung01 trial results.
.jpg?fit=crop&auto=format)
